Kisspeptin Alleviates Human Hepatic Fibrogenesis by Inhibiting TGFβ Signaling in Hepatic Stellate Cells.

Autor: Prasad, Kavita¹ (AUTHOR) kp460@connect.rutgers.edu, Bhattacharya, Dipankar² (AUTHOR) dipankar.bhattacharya@mssm.edu, Shams, Shams Gamal Eldin¹ (AUTHOR) ss4459@rwjms.rutgers.edu, Izarraras, Kimberly¹ (AUTHOR) ki113@gsbs.rutgers.edu, Hart, Tia¹ (AUTHOR) tmh187@cinj.rutgers.edu, Mayfield, Brent³ (AUTHOR) bcm2151@cumc.columbia.edu, Blaszczyk, Maryjka B.⁴ (AUTHOR) mb2001@rwjms.rutgers.edu, Zhou, Zhongren⁴ (AUTHOR) zz442@rwjms.rutgers.edu, Pajvani, Utpal B.³ (AUTHOR) up2104@cumc.columbia.edu, Friedman, Scott L.² (AUTHOR) scott.friedman@mssm.edu, Bhattacharya, Moshmi¹ (AUTHOR) mb1722@rutgers.edu

Publikováno v: Cells (2073-4409). Oct2024, Vol. 13 Issue 19, p1651. 19p.

Brain RFamide Neuropeptides in Stress-Related Psychopathologies.

Autor: Kovács, Anita¹ (AUTHOR) anita.kovacs@aok.pte.hu, Szabó, Evelin¹ (AUTHOR) szabo.evelin9812@gmail.com, László, Kristóf¹ (AUTHOR) kristof.laszlo@aok.pte.hu, Kertes, Erika¹ (AUTHOR) erika.kertes@aok.pte.hu, Zagorácz, Olga¹ (AUTHOR) olga.zagoracz@aok.pte.hu, Mintál, Kitti¹ (AUTHOR) kitti.mintal@aok.pte.hu, Tóth, Attila¹ (AUTHOR) attila.toth@aok.pte.hu, Gálosi, Rita¹ (AUTHOR) rita.galosi@aok.pte.hu, Berta, Bea¹ (AUTHOR) beata.berta@aok.pte.hu, Lénárd, László¹ (AUTHOR) laszlo.lenard@aok.pte.hu, Hormay, Edina¹ (AUTHOR) edina.hormay@aok.pte.hu, László, Bettina¹ (AUTHOR) bettina.csetenyi@aok.pte.hu, Zelena, Dóra¹ (AUTHOR) zelena.dora@pte.hu, Tóth, Zsuzsanna E.² (AUTHOR) zelena.dora@pte.hu

Publikováno v: Cells (2073-4409). Jul2024, Vol. 13 Issue 13, p1097. 40p.

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.

Autor: Petrova PS; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Viller NN; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Wong M; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Pang X; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Lin GH; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Dodge K; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Chai V; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Chen H; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Lee V; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., House V; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Vigo NT; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Jin D; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Mutukura T; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Charbonneau M; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Truong T; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Viau S; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Johnson LD; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Linderoth E; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Sievers EL; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Maleki Vareki S; London Regional Cancer Program, London Health Sciences Centre, Lawson Heath Research Institute, London, Ontario, Canada.; Department of Oncology, University of Western Ontario, London, Ontario, Canada., Figueredo R; London Regional Cancer Program, London Health Sciences Centre, Lawson Heath Research Institute, London, Ontario, Canada.; Department of Oncology, University of Western Ontario, London, Ontario, Canada., Pampillo M; London Regional Cancer Program, London Health Sciences Centre, Lawson Heath Research Institute, London, Ontario, Canada., Koropatnick J; London Regional Cancer Program, London Health Sciences Centre, Lawson Heath Research Institute, London, Ontario, Canada.; Department of Oncology, University of Western Ontario, London, Ontario, Canada., Trudel S; Princess Margaret Cancer Center, University Health Network (UHN), Toronto, Ontario, Canada., Mbong N; Princess Margaret Cancer Center, University Health Network (UHN), Toronto, Ontario, Canada., Jin L; Princess Margaret Cancer Center, University Health Network (UHN), Toronto, Ontario, Canada., Wang JC; Princess Margaret Cancer Center, University Health Network (UHN), Toronto, Ontario, Canada.; Division of Medical Oncology and Hematology, Department of Medicine, UHN, and Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Uger RA; Trillium Therapeutics Inc., Mississauga, Ontario, Canada. bob@trilliumtherapeutics.com.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2017 Feb 15; Vol. 23 (4), pp. 1068-1079. Date of Electronic Publication: 2016 Nov 17.

Gallium-68-Labeled KISS1-54 Peptide for Mapping KISS1 Receptor via PET: Initial Evaluation in Human Tumor Cell Lines and in Tumor-Bearing Mice.

Autor: Israel, Ina¹ (AUTHOR) israel_i@ukw.de, Riehl, Gabriele¹ (AUTHOR) riehl_g@ukw.de, Butt, Elke² (AUTHOR) butt_e@ukw.de, Buck, Andreas K.¹ (AUTHOR) buck_a@ukw.de, Samnick, Samuel¹ (AUTHOR) samnick_s@ukw.de

Publikováno v: Pharmaceuticals (14248247). Jan2024, Vol. 17 Issue 1, p44. 14p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.